Investor Relations

Our equity story - 5 reasons to invest in Evotec

1. Answering the external innovation megatrend: Through ebbs and flows of the drug discovery landscape, Evotec has continued to support the needs of its clients with best-in-class services. The flexibility of the business model allows the Company to scale the product offering depending on individual client needs. As a result and more than ever before, the Company is positioned to meet the increased demand of the outsourcing megatrend.
2. Unrivalled scientific expertise and cutting-edge technology: With globally more than 3,000 employees and 2,200 top-class scientists of 69 different nationalities, we are experts when it comes to identifying new ways of accelerating innovation. Our scientists do not only impress with a high level of education, but also with their everlasting passion for science, creativity and dedication. Evotec’s comprehensive, unbiased and cutting-edge drug discovery platform for external innovation has been built up with this expertise over many years. It has a long-lasting track record in delivering successful integrated and standalone projects to Evotec’s partners.
3. Strong ties to Biopharma and Academic networks: Our multi-faceted corporate strategy is informed by our strong collaborative partnerships that provide access to key opinion leaders within top academic institutions and leading Biopharma companies. Evotec’s corporate and institutional partnerships allow the Company to continually adopt creative ways to stay in tune with and accelerate innovation.
4. Strong and experienced senior management: The leadership team’s comprehensive experience and deep relationships provide valuable insight into many angles of the industry. The Company leverages insight provided by leadership to better understand client needs and subsequently deliver value by helping clients navigate the complex drug discovery landscape.
5. Hybrid business model for sustainable success: EVT Innovate, the Company’s innovation segment, is primarily financed through re-investing earnings of EVT Execute, the Company’s service segment, which along with a co-owned pipeline, results in a biotech business with a unique risk profile and significant potential for future value creation.